江子
Lv1
20 积分
2022-09-06 加入
-
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial
13天前
已完结
-
Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment
14天前
已完结
-
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial
4个月前
已完结
-
Impact of Pembrolizumab Versus Chemotherapy on Health-Related Quality of Life in Patients With Metastatic Triple-Negative Breast Cancer: Results From the Phase 3 Randomized KEYNOTE-119 Study
4个月前
已完结
-
[Guidelines for clinical application of platinum drugs in breast cancer (2023 edition)]
4个月前
已完结
-
Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
5个月前
已完结
-
[Efficacy of neoadjuvant therapy on HER2-positive breast cancer: a clinicopathological analysis]
5个月前
已完结
-
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
5个月前
已完结
-
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
5个月前
已完结
-
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
5个月前
已完结